CN116492242A - Alopecia preventing composition, preparation method and application thereof - Google Patents
Alopecia preventing composition, preparation method and application thereof Download PDFInfo
- Publication number
- CN116492242A CN116492242A CN202310428345.6A CN202310428345A CN116492242A CN 116492242 A CN116492242 A CN 116492242A CN 202310428345 A CN202310428345 A CN 202310428345A CN 116492242 A CN116492242 A CN 116492242A
- Authority
- CN
- China
- Prior art keywords
- hair
- parts
- hair loss
- alopecia
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 77
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000003405 preventing effect Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000003656 anti-hair-loss Effects 0.000 claims abstract description 47
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 claims abstract description 28
- NFPWMUOQSJXGGZ-ZZTWKDBPSA-N N-[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O NFPWMUOQSJXGGZ-ZZTWKDBPSA-N 0.000 claims abstract description 26
- 210000004209 hair Anatomy 0.000 claims description 32
- 230000003779 hair growth Effects 0.000 claims description 28
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 claims description 20
- 241000208822 Lactuca Species 0.000 claims description 20
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 abstract description 22
- 230000003676 hair loss Effects 0.000 abstract description 21
- 239000000047 product Substances 0.000 abstract description 11
- 210000000442 hair follicle cell Anatomy 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
- 210000004761 scalp Anatomy 0.000 description 15
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 13
- 229960003604 testosterone Drugs 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000003780 hair follicle Anatomy 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 9
- 229960005323 phenoxyethanol Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 8
- 229960003473 androstanolone Drugs 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 208000001840 Dandruff Diseases 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 3
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000031774 hair cycle Effects 0.000 description 3
- 229940044591 methyl glucose dioleate Drugs 0.000 description 3
- 230000003658 preventing hair loss Effects 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000000280 densification Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- AJPXZTKPPINUKN-UHFFFAOYSA-N Isoliensinin Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-UHFFFAOYSA-N 0.000 description 1
- AJPXZTKPPINUKN-FIRIVFDPSA-N Isoliensinine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-FIRIVFDPSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- MIBATSHDJRIUJK-ROJLCIKYSA-N Neferine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-ROJLCIKYSA-N 0.000 description 1
- MIBATSHDJRIUJK-UHFFFAOYSA-N Neferine Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical group O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a hair loss composition, a preparation method and application thereof. The invention relates to the technical field of cosmetics, in particular to an anti-hair loss composition, a preparation method and application thereof. The hair loss composition comprises diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuceoside B. The invention also provides a preparation method of the composite. Compared with the prior art, the alopecia composition prepared by the invention has the advantages that the substances are synergistic, supplement each other, slow down alopecia, promote proliferation and growth of hair follicle cells, improve the alopecia preventing effect, and effectively solve the problem that the alopecia preventing product in the prior art can only slow down alopecia.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to an anti-hair loss composition, a preparation method and application thereof.
Background
With the rapid development of society, the life pressure and working pressure of people are increased, and the alopecia phenomenon is serious, so that the alopecia phenomenon becomes a common phenomenon of the society. Alopecia not only affects the external image of people, but also has great influence on the visual sense of people, and even affects the self-confidence of people. A plurality of alopecia preventing products exist in the market at present, and most of the alopecia preventing products can only slow down the problem of hair falling.
The CN108578269A composition with hair-nourishing and hair-loss-preventing effects, cosmetics, essence and a preparation method of the essence, disclosed by the invention, comprises the following raw materials in parts by weight: 0.001-10 parts of tripeptide-1 copper, 0.01-5 parts of biotin, 0.01-10 parts of nicotinamide, 0.01-20 parts of panthenol and a solvent. The composition with the effects of hair growth and hair loss prevention has the effects of promoting blood circulation, promoting hair regeneration, preventing hair loss, nourishing scalp and hair roots, repairing hair follicles and the like. The cosmetics and the essence containing the composition having hair-growing and hair-loss preventing effects may also have the effects of the composition having hair-growing and hair-loss preventing effects. But the effect is to be further improved.
Disclosure of Invention
In order to achieve the above object, the present invention provides an anti-hair loss composition characterized in that: including diaminopyrimidine oxide, myristoyl pentapeptide-17, and lettuceoside B.
Further preferably, the alopecia preventing composition comprises the following raw materials in parts by weight: 30-50 parts of diaminopyrimidine oxide, 30-50 parts of myristoyl pentapeptide-17 and 10-30 parts of lettuceoside B.
Diaminopyrimidine oxide, chemically named 2, 4-diaminopyrimidine-3-oxide, is structurally similar to minoxidil, increasing cellular metabolism: the diaminopyrimidine oxide can stimulate the metabolic activity of hair follicle cells, improve the activity of the cells, optimize the hair growth cycle, promote hair growth, and possibly slow down hair follicle atrophy and hair loss by inhibiting the production or action of androgens. The diaminopyrimidine oxide can effectively inhibit network densification of fibronectin and collagen by inhibiting synthesis of lysine hydroxylase, so that 'soil hardening' of fibrosis around hair follicles is resisted, the hair follicles can be rooted more firmly, and alopecia is effectively and obviously prevented.
Myristoyl pentapeptide-17 (Myristoyl Pentapeptide-17, MP17P) is myristoylated pentapeptide Lys-Leu-Ala-Lys-Lys, which is effective in stimulating keratin synthesis of hair, promoting hair growth, and thickening and toughening hair.
Lettuce glycoside B is a natural plant extract, and inhibits 5α -reductase activity, an enzyme that converts testosterone into dihydrotestosterone. Dihydrotestosterone is considered to be one of the main causes of male pattern alopecia. Lettuce glycoside B can reduce the production of dihydrotestosterone by inhibiting 5α -reductase, thereby slowing down hair loss; lettuce glycoside B can also promote blood circulation of the scalp, thereby increasing oxygen and nutrient supply to the scalp, which is important for promoting hair growth and slowing down hair loss; lettuce glycoside B has certain antioxidation effect, and can reduce damage of free radicals to hair, which helps to protect hair from damage and promote hair growth.
The diaminopyrimidine oxide, the myristoyl pentapeptide-17 and the lettuceoside B have synergistic effect on preventing alopecia. Specifically, diaminopyrimidine oxide stimulates the metabolic activity of hair follicle cells, increases cell viability, thereby optimizing the hair growth cycle, promoting hair growth, and simultaneously, by inhibiting the production or action of androgens, slowing down hair follicle atrophy and hair loss. Myristoyl pentapeptide-17 stimulates keratin synthesis in hair, promotes hair growth, and thickens and toughens hair. Lettuce glycoside B can inhibit 5 alpha-reductase activity, thereby reducing the production of dihydrotestosterone, slowing down alopecia, promoting scalp blood circulation, increasing scalp oxygen and nutrition supply, and helping to promote hair growth and slow down alopecia. Therefore, from the action mechanisms of the three components, a synergistic effect is considered to be generated between the three components, so that a better alopecia preventing effect is achieved, alopecia is slowed down, proliferation and growth of hair follicle cells are promoted, and the problem that the alopecia preventing product in the prior art can only slow down alopecia is effectively solved.
The invention also discloses a preparation method of the alopecia preventing composition.
A method for preparing an anti-hair loss composition, comprising the steps of: diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuce glycoside B were mixed.
The invention also discloses an anti-hair loss product.
An anti-hair loss and hair growth product comprises the anti-hair loss composition.
The hair loss preventing and hair growing product is hair loss preventing essence, hair growing cream, hair growing liquid, shampoo or hair conditioner.
The preparation method of the hair loss preventing and growing product comprises the following steps of mixing the hair loss preventing composition with conventional raw materials and preparing the hair loss preventing composition according to a conventional process.
The invention relates to an application of an anti-hair loss composition.
The invention relates to an application of an anti-hair loss composition in the fields of anti-hair loss and hair growth.
The invention has the beneficial effects that:
in the application, diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuce glycoside B are used as raw materials, the substances are synergistic, supplement each other, slow down alopecia and shed hair, promote proliferation and growth of hair follicle cells, improve the alopecia preventing effect, and effectively solve the problem that the alopecia preventing product in the prior art can only slow down alopecia. After the hair-loss cream is continuously used for 3 months for volunteers, dandruff and spasm itching are relieved, alopecia is reduced, new generation of hair is sprouted, excessive secretion of sebum is inhibited, the appearance is improved, and the scalp environment is effectively improved.
Detailed Description
The technical scheme of the present invention will be described in detail by means of specific examples, which should be explicitly set forth for illustration, but should not be construed as limiting the scope of the present invention.
Examples
The alopecia preventing composition consists of the following raw materials in parts by weight: 30 parts of diaminopyrimidine oxide, 30 parts of myristoyl pentapeptide-17 and 10 parts of lettuceoside B.
Examples
The alopecia preventing composition consists of the following raw materials in parts by weight: 50 parts of diaminopyrimidine oxide, 50 parts of myristoyl pentapeptide-17 and 30 parts of lettuceoside B.
Examples
The alopecia preventing composition consists of the following raw materials in parts by weight: 40 parts of diaminopyrimidine oxide, 40 parts of myristoyl pentapeptide-17 and 20 parts of lettuceoside B.
Examples
The alopecia preventing composition consists of the following raw materials in parts by weight: 40 parts of diaminopyrimidine oxide and 40 parts of myristoyl pentapeptide-17.
Examples
The alopecia preventing composition consists of the following raw materials in parts by weight: 40 parts of myristoyl pentapeptide-17 and 20 parts of lettuce glycoside B.
Examples
The alopecia preventing composition consists of the following raw materials in parts by weight: 40 parts of diaminopyrimidine oxide and 20 parts of lettuce glycoside B.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of the alopecia preventing composition obtained in example 1, 2 parts of propylene glycol, 1.1 parts of PEG-120 methylglucinol dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of the alopecia preventing composition obtained in example 2, 2 parts of propylene glycol, 1.1 parts of PEG-120 methylglucinol dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of the alopecia preventing composition obtained in example 3, 2 parts of propylene glycol, 1.1 parts of PEG-120 methylglucinol dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of the alopecia preventing composition obtained in example 4, 2 parts of propylene glycol, 1.1 parts of PEG-120 methylglucinol dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of the alopecia preventing composition obtained in example 5, 2 parts of propylene glycol, 1.1 parts of PEG-120 methylglucinol dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of the alopecia preventing composition obtained in example 6, 2 parts of propylene glycol, 1.1 parts of PEG-120 methylglucinol dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of diaminopyrimidine oxide, 2 parts of propylene glycol, 1.1 parts of PEG-120 methyl glucose dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of myristoyl pentapeptide-17, 2 parts of propylene glycol, 1.1 parts of PEG-120 methyl glucose dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
The anti-hair loss essence comprises the following components in parts by weight: 5 parts of lettuce glycoside B, 2 parts of propylene glycol, 1.1 parts of PEG-120 methyl glucose dioleate, 0.4 part of citric acid, 0.5 part of phenoxyethanol and 91 parts of water.
Reference (study of 5. Alpha. -reductase inhibition by neferine and isoliensinine, yang Xiaoqing et al, chinese physician, 2016) was made in section 1.3.
Six week old male clean grade SD rats were anesthetized with diethyl ether, their prostates were removed under sterile conditions and weighed. Then, the prostate tissue is minced and 5 times volume of pre-chilled buffer solution is added, wherein the buffer solution consists of Tris 120.5mg, EDTA-2Na 1.7mg, mgCl 2 ·6H 2 100mg of O, 3.9mg of 2-mercaptoethanol, 0.3g of NaCl and 4.5g of sucrose are filled into a 100mL volumetric flask, double distilled water is used for constant volume to 100mL, the pH value is regulated to 6.3, homogenization is carried out in ice bath at the speed of 20000r/min, and 10000r/min is carried out at the temperature of 4 DEG CCentrifuging at speed for 1 hr, carefully removing white fat on the upper layer of the centrifugate, collecting supernatant to obtain 5α -reductase extract, measuring protein content of 0.991mg/mL with Coomassie Brilliant blue, subpackaging, and storing in a refrigerator at-80deg.C.
RP-HPLC chromatographic conditions were: the mobile phase is methanol-water (80:20 v/v), ultrasonic degassing is carried out for 1h, the flow rate is 1.0ml/min, the detection wavelength is 242nm, the column temperature is 32 ℃, and the sample injection amount is 20 mu L. Preparation of testosterone standard curve: accurately weighing testosterone standard reference substance, preparing into 1mg/ml standard solution with methanol, diluting into different concentrations, respectively taking different concentration standard solutions for sample injection, repeating for 3 times, measuring peak area, drawing with peak area mean value and concentration in the concentration range of 0-100 μg/ml, and drawing standard curve.
The experiment is divided into 11 groups, including a blank control group, a positive control group and an experimental group, the reaction system comprises 120 mu L of testosterone with the concentration of 60 mu M, 60 mu L of 5 alpha-reductase extract, 60 mu L of an object to be detected and 120 mu M of NADPH with the concentration of 120 mu L, and the volumes of the object to be detected in the blank control group, the positive control group and the experimental group are the same, and are respectively water, ilapride and the anti-hair loss essence obtained in application examples 1-9. And (3) reacting each mixed system for 15min at 37 ℃, injecting 20 mu L of sample, substituting the testosterone peak area in the sample into a standard curve, and calculating the corresponding concentration. The testosterone concentration of the anti-hair loss essence obtained in application examples 1-9 is subtracted by the testosterone concentration of the 5 alpha-reductase sample to obtain the testosterone concentration after the substrate reaction, the testosterone concentration of the sample without NADPH is used as the testosterone concentration of the substrate before the reaction, and the testosterone concentration difference delta CT of the substrate before and after the reaction is obtained. According to the definition of the unit of enzyme activity, the unit concentration enzyme solution catalyzes the substrate to reduce per minute at 37 ℃ and the pH=6.2 is one unit of enzyme activity, and the calculation formula is as follows: 5α -reductase activity (U/L) =Δct/(15×0.989×60×10) -3 ). The inhibition rate calculation formula: i% = (Δa) 0 -ΔA n )/ΔA 0 X 100%. Wherein DeltaA 0 5 alpha-reductase Activity, deltaA, for the blank control group n Is 5 alpha-reductase activity of the test group.
Table 1 test results of inhibition of anti-hair loss essence
As is clear from table 1, the inhibition effect of application example 3 is significantly better than that of application 1-2, and the anti-hair loss composition employed in application example 3 has an excellent inhibition effect at a specific ratio under the same experimental conditions. The inhibition effect of application example 3 is obviously better than that of application examples 4-6, which shows that the synergistic effect of diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuceoside B improves the inhibition effect of 5 alpha-reductase.
Androgenic alopecia patients were collected as subjects according to the inclusion criteria, aged 23-50 years, with a course of disease of up to 3 years and 2 months, a minimum of 3 months, and an average of 8 months. The above androgenic alopecia patients were randomly grouped, 15 persons per group.
1. Condition of selection:
1, androgenetic alopecia patients with age 20-50 years old;
2. is healthy;
3. hormones, immunosuppressants, hair-growing drugs and other related hair-growing cosmetics have not been used recently;
4. the patient does not participate in other clinical tests and voluntarily participates in the test to finish the specified content according to the requirement;
5. informed consent was filled in as required for the clinical trial.
2. Exclusion conditions:
1, the selected standard is not met;
2. allergic people to alcohol preparations or other hair care products;
3. the skull is now afflicted with infectious, inflammatory or other skin lesion disease.
The test method comprises the following steps:
the anti-hair loss essence obtained in application examples 1-9 was uniformly applied to scalp and hair roots, the scalp was gently massaged to absorption, twice a day and a night, one month was a treatment course, three treatment courses were taken, the blank control group was applied with an aqueous ethanol solution, the volume fraction of ethanol in the aqueous ethanol solution was 50%, and the test was a double-blind test.
The curative effect judgment standard is as follows: (1) no change: the conditions of head oil, dandruff and alopecia are not improved, fine hair germination is not seen, and the appearance improvement is not obvious; (2) slight improvement: the itching feeling is reduced, the dandruff and the alopecia are reduced, the scalp environment is partially improved, and no new occurrence is seen. (3) significant improvement: the dandruff and the spasm itching are relieved, the alopecia is reduced, the new generation is started, the excessive secretion of sebum is inhibited, the appearance is improved, and the scalp environment is effectively improved.
Table 2 anti-hair loss test results of anti-hair loss essence
As can be seen from table 2, the anti-hair loss effect of application example 3 is significantly better than that of application examples 1-2, and under the same experimental conditions, the anti-hair loss composition adopted in application example 3 has excellent inhibition effect under a specific proportion, and in the application, diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuce glycoside B are used as raw materials, and are mixed according to a specific proportion, and the substances are synergistic, mutually complement, so that hair loss is slowed down, proliferation and growth of hair follicle cells are promoted, the anti-hair loss effect is improved, and the problem that the anti-hair loss product in the prior art can only slow down hair loss is effectively solved.
The alopecia preventing effect of the application example 3 is obviously better than that of the application examples 4-6 through comparing the application example 3 with the application examples 4-6, the slight improvement rate and the obvious improvement rate are obviously higher than those of the application examples 4-6, the dandruff and the spasm itching are relieved, the alopecia is reduced, new occurrence is generated, excessive secretion of sebum is inhibited, and the scalp environment is effectively improved.
The research and test method of the hair loss prevention essence applied to the effect of the hair growth of the mice comprises the following steps: six clean SD rats were kept for 100 weeks old, dehairing was performed on the back 2cm x 2cm area of the mice after normal feeding for one week (the mice were spread on the back designated area of the mice after melting by heating with a mixture of rosin and paraffin in a weight ratio of 1:1), and then the mice were randomly divided into 10 groups of 10 animals each, wherein 1 group served as a blank control group was spread with physiological saline only, the rest of each group was spread with anti-hair loss essence in each example of 20mg/kg, each time in the morning and evening for 3 weeks, and the hair length and hair weight of the mice in the test area were measured.
Table 3 test results of anti-hair loss essence
As is clear from table 3, the anti-hair loss essence obtained in the present application has a good hair growth promoting effect.
The diaminopyrimidine oxide can stimulate metabolism of hair follicle cells, improve cell activity, optimize hair growth cycle, and promote hair growth. In addition, it can also slow down hair follicle atrophy and hair loss by inhibiting the production or action of androgens. The diaminopyrimidine oxide can effectively inhibit the synthesis of lysine hydroxylase, and further inhibit the network densification of fibronectin and collagen, so that the occurrence of 'soil hardening' of fibrosis around hair follicles is resisted, the hair follicles can be rooted more firmly, and alopecia is effectively and obviously prevented.
Myristoyl pentapeptide-17 stimulates keratin synthesis in hair, promotes hair growth, and thickens and toughens hair. It can stimulate the growth of hair follicle cells and promote the growth cycle of hair. In addition, myristoyl pentapeptide-17 can also increase energy metabolism of hair follicle cells and improve the biological activity of the cells.
Lettuce glycoside B inhibits 5α -reductase, an enzyme that converts testosterone to dihydrotestosterone. Dihydrotestosterone is considered to be one of the main causes of male pattern alopecia. Lettuce glycoside B can reduce the production of dihydrotestosterone by inhibiting 5α -reductase, thereby slowing down hair loss; lettuce glycoside B can also promote blood circulation of the scalp, thereby increasing oxygen and nutrient supply to the scalp, which is important for promoting hair growth and slowing down hair loss; lettuce glycoside B has certain antioxidation effect, and can reduce damage of free radicals to hair, which helps to protect hair from damage and promote hair growth.
In summary, the synergistic mechanism of diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuce glycoside B in terms of anticreep mainly comprises:
the diaminopyrimidine oxide can promote metabolism of hair follicle cells, improve cell activity, inhibit synthesis of lysine hydroxylase, inhibit perifollicular fibrosis, and prevent hair follicle atrophy and hair loss.
Myristoyl pentapeptide-17 stimulates keratin synthesis in hair, promotes hair growth, and thickens and toughens hair.
Lettuce glycoside B can inhibit 5 alpha-reductase activity, reduce the production of dihydrotestosterone, and slow down alopecia; promoting blood circulation of scalp, increasing oxygen and nutrition supply of scalp, promoting hair growth and relieving alopecia; the antioxidant effect can reduce damage of free radicals to hair, protect hair from damage, and promote hair growth.
The three components can complement each other in synergistic effect, and can improve alopecia preventing effect. The diaminopyrimidine oxide and the lettuce glycoside B can inhibit the production or action of male hormone, slow down the atrophy of hair follicles and the shedding of hair, and simultaneously, the myristoyl pentapeptide-17 can promote the growth and the thickening of hair and improve the health state of the hair. The synergistic effect of the three components can reduce hair loss, and increase hair growth and health, thereby achieving the purpose of preventing alopecia.
Claims (8)
1. An anti-hair loss composition, characterized in that the raw materials comprise: at least two of diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuce glycoside B.
2. An anti-hair loss composition is characterized by comprising the following raw materials: diaminopyrimidine oxide, myristoyl pentapeptide-17 and lettuce glycoside B.
3. The alopecia preventing composition of claim 1, comprising the following materials in parts by weight: 30-50 parts of diaminopyrimidine oxide, 30-50 parts of myristoyl pentapeptide-17 and 10-30 parts of lettuceoside B.
4. A method for preparing an anti-hair loss composition is characterized in that diaminopyrimidine oxide, myristoylpentapeptide-17 and lettuceoside B are mixed.
5. An anti-hair loss and hair growth product characterized in that the anti-hair loss composition according to claim 1 or 2 is an anti-hair loss essence, a hair growth cream, a hair growth liquid, a shampoo or a conditioner.
6. A method for preparing an anti-hair loss product, characterized in that the anti-hair loss composition according to claim 1 or 2 is mixed with conventional raw materials and prepared according to conventional processes.
7. Use of the anti-hair loss composition according to claim 1 or 2 for the preparation of an anti-hair loss hair growth product.
8. The use of the anti-hair loss composition according to claim 6 for preparing an anti-hair loss and hair growth product, wherein the anti-hair loss and hair growth product is an anti-hair loss essence, a hair growth cream, a hair growth liquid, a shampoo or a hair conditioner.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310428345.6A CN116492242A (en) | 2023-04-20 | 2023-04-20 | Alopecia preventing composition, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310428345.6A CN116492242A (en) | 2023-04-20 | 2023-04-20 | Alopecia preventing composition, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116492242A true CN116492242A (en) | 2023-07-28 |
Family
ID=87324117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310428345.6A Pending CN116492242A (en) | 2023-04-20 | 2023-04-20 | Alopecia preventing composition, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116492242A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105395566A (en) * | 2015-12-08 | 2016-03-16 | 新乡医学院 | Application of lactuside B in preparation of drugs preventing or treating alopecia |
| CN110200838A (en) * | 2019-06-21 | 2019-09-06 | 武汉百思凯瑞生物科技有限公司 | A kind of complex polypeptide nano vesicle and its preparation method and application |
| CN114344188A (en) * | 2022-01-14 | 2022-04-15 | 四川暨康生物医药科技有限公司 | Hair loss prevention and hair growth promoting composition and preparation method thereof |
| CN115177545A (en) * | 2022-08-29 | 2022-10-14 | 重庆市食品药品检验检测研究院 | Hair growth liquid with high curative effect and few side effects and preparation method thereof |
-
2023
- 2023-04-20 CN CN202310428345.6A patent/CN116492242A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105395566A (en) * | 2015-12-08 | 2016-03-16 | 新乡医学院 | Application of lactuside B in preparation of drugs preventing or treating alopecia |
| CN110200838A (en) * | 2019-06-21 | 2019-09-06 | 武汉百思凯瑞生物科技有限公司 | A kind of complex polypeptide nano vesicle and its preparation method and application |
| CN114344188A (en) * | 2022-01-14 | 2022-04-15 | 四川暨康生物医药科技有限公司 | Hair loss prevention and hair growth promoting composition and preparation method thereof |
| CN115177545A (en) * | 2022-08-29 | 2022-10-14 | 重庆市食品药品检验检测研究院 | Hair growth liquid with high curative effect and few side effects and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585097B (en) | Epidermal growth factor-loaded bletilla rhizome polysaccharide compound, and preparation method and application thereof | |
| CN105106028A (en) | Polypeptide composition for hair growth | |
| KR102493443B1 (en) | Cosmetic composition comprising extracts extracted with an eco-friendly natural eutectic solvent | |
| CN113908091B (en) | Anti-hair-loss hair-growing composition and preparation method and application thereof | |
| KR20120039384A (en) | The hair growth compositions containing flavonoids | |
| CN112402358B (en) | Probiotic plant fermentation product with hair loss prevention function and preparation method thereof | |
| KR20190091162A (en) | Cosmetic Composition for Improving Skin and Hair Condition Containing Green Tea Leaf Fermentation Extract | |
| CN116036196B (en) | Anti-hair loss hair-nourishing essence and preparation method thereof | |
| CN113368018A (en) | Anti-inflammatory acne-removing composition and preparation method thereof | |
| CN112870333A (en) | Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof | |
| CN110064039B (en) | Anti-hair loss and hair-nourishing composition and application thereof | |
| CN114042001A (en) | Whitening composition with synergistic effect and application thereof | |
| KR101114307B1 (en) | Hair growth agent composition | |
| KR101066797B1 (en) | Hair growth agent composition | |
| CN116492242A (en) | Alopecia preventing composition, preparation method and application thereof | |
| KR100482667B1 (en) | Composition for external application to the skin containing D-Fructose 1,6 diphosphate | |
| CN112535656B (en) | Probiotic plant fermentation product with hair blacking function and preparation method | |
| KR102552523B1 (en) | Hair cosmetic composition for improving hair loss and white hair | |
| CN113633585B (en) | External hair care composition and preparation with effects of preventing alopecia, promoting hair growth and blackening hair and preparation method thereof | |
| CN113768803A (en) | Composition of spray for preventing alopecia and removing dandruff and preparation method | |
| CN113384483A (en) | Composition for improving skin elasticity and delaying aging and preparation method thereof | |
| CN112120984B (en) | Composition for moisturizing and brightening skin and application thereof | |
| KR101078595B1 (en) | Hair Cosmetic Composition for Anti-Dandruff, Preventing the Hair Loss and Promoting the Hair Growth Comprising Phaseolus radiatus extracts by Fermentation and Enzyme Treatment | |
| CN116370525A (en) | Plant fermentation composition for preventing hair loss and growing hair as well as preparation method and application thereof | |
| CN116350535A (en) | Hair-fixing and developing composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230728 |